• Ovarian
  • This is a randomized open-label study to compare between in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes of the two regimen of Cetrotide® (Cetrorelix acetate) which are 0.25 milligram (mg) used from Day 1 or Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in assisted reproductive technology (ART). (clinicaltrials.gov)
  • Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. (globenewswire.com)
  • cells
  • Timothy P. Coleman, Ph.D., Chairman, Chief Executive Officer and President of Nemucore commented, "NMI-8000 represents a completely novel therapeutic class of agents capable of treating female reproductive cancers by preferentially eliminating MIS type II receptor cells often associated with the chemo-resistant cancer stem cell fraction of the tumor. (globenewswire.com)
  • female
  • NMI-8000 is the biologically active form of Müllerian Inhibitory Substance (MIS), which targets MIS type II receptor-positive cancers often associated with the female reproductive system. (globenewswire.com)
  • potential
  • Although the therapeutic potential of MIS has long been recognized by the oncology community, until now, no one has been able to produce this biologic in enough quantity to initiate clinical trial development. (globenewswire.com)